Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 12/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 5/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379232 | 0.83 | RXRA (0.42) | NOTUMCYP19A1RXRAGRIN1GRIN2B | |
| SCHEMBL29471936 | 0.82 | NOTUM (0.65) | NOTUMRXRAGRIN1GRIN2BKEAP1 | |
| SCHEMBL28266369 | 0.82 | NOTUM (0.65) | NOTUMRXRAGRIN1GRIN2BKEAP1 | |
| SCHEMBL10447781 | 0.79 | NOTUM (0.78) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL28166936 | 0.77 | NOTUM (0.67) | NOTUMCYP19A1KEAP1L3MBTL1 | |
| SCHEMBL16556797 | 0.76 | NOTUM (0.53) | NOTUMRXRAGRIN1GRIN2BPOLB | |
| SCHEMBL28071272 | 0.76 | NOTUM (0.58) | NOTUMCYP19A1RXRAGRIN1GRIN2B | |
| SCHEMBL6276669 | 0.76 | KMT2A (0.54) | NOTUMPOLB | |
| SCHEMBL29084891 | 0.75 | NOTUM (0.65) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL21777006 | 0.74 | NOTUM (1.00) | NOTUMCYP19A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285850-B | Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| CN-105524058-B | Pyrazolo [1,5 a] pyridine compounds and their and its application | 广州艾格生物科技有限公司 | 2018-03-27 | — | — | CN | disclosed |
| EP-2967073-A1 | LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152738-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041578-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | CRBN, CUL4B, UBQLN1 | NOTUM 4254/4885CYP19A1 1469/4885RXRA 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.